Snehashis Roy
Research Subjects
Snehashis Roy has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Carass
Johns Hopkins University
27 shared publications - Jerry L. Prince
Johns Hopkins University
16 shared publications Dzung L. Pham
Center for Neuroscience and Regenerative Medicine, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
13 shared publicationsJerry L. Prince
Dept. of Electrical and Computer Engineering, The Johns Hopkins University, United States
12 shared publications- Peter Arthur Calabresi
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6 shared publications Dzung Pham
Center for Neuroscience and Regenerative Medicine, Henry Jackson Foundation, Bethesda, Maryland
5 shared publications
Latest Publications
- Open Access
Mesoscopic analysis of GABAergic marker expression in acetylcholine neurons in the whole mouse brain
In the central nervous system, acetylcholine (ACh) neurons coordinate neural network activity required for higher brain functions, such as attention, learning, and memory, as well as locomotion. Disturbances in cholinergic signaling have been described in many diseases of the developing and mature brain. Interestingly, ACh neurons can co-transmit GABA to support essential roles in brain function. However, the contributions of ACh/GABA co-transmission to brain function remain unclear. This underscores the need to better understand the heterogeneity of ACh neurons, particularly the sub-population of ACh neurons co-expressing GABAergic markers. We used various combinations of transgenic mouse lines to systematically label ACh neuron populations positive for different GABAergic markers in the brain. We developed a workflow combining tissue clearing, light-sheet fluorescence microscopy, and machine learning to image entire mouse brain hemispheres followed by quantification of ACh neurons throughout the brain. With this approach, we assessed the role of GABA co-transmission in ACh neuron function and quantified ACh and ACh/GABA neuron sub-populations in the brain. Our results suggest that GABA co-transmission from ACh neurons is not required to maintain the regular ACh neuron count in the brain. Furthermore, we report that a large subset of ACh neurons can potentially synthesize GABA by co-expressing the marker Gad2. However, most of these ACh neurons do not express vGAT, which would enable these neurons to release GABA. Taken together, we conclude that GABA co-transmission likely occurs only from a small population of ACh neurons restricted to few brain nuclei.
Open AccessMesoscopic analysis of GABAergic marker expression in acetylcholine neurons in the whole mouse brain
In the central nervous system, acetylcholine (ACh) neurons coordinate neural network activity required for higher brain functions, such as attention, learning, and memory, as well as locomotion. Disturbances in cholinergic signaling have been described in many diseases of the developing and mature brain. Interestingly, ACh neurons can co-transmit GABA to support essential roles in brain function. However, the contributions of ACh/GABA co-transmission to brain function remain unclear. This underscores the need to better understand the heterogeneity of ACh neurons, particularly the sub-population of ACh neurons co-expressing GABAergic markers. We used various combinations of transgenic mouse lines to systematically label ACh neuron populations positive for different GABAergic markers in the brain. We developed a workflow combining tissue clearing, light-sheet fluorescence microscopy, and machine learning to image entire mouse brain hemispheres followed by quantification of ACh neurons throughout the brain. With this approach, we assessed the role of GABA co-transmission in ACh neuron function and quantified ACh and ACh/GABA neuron sub-populations in the brain. Our results suggest that GABA co-transmission from ACh neurons is not required to maintain the regular ACh neuron count in the brain. Furthermore, we report that a large subset of ACh neurons can potentially synthesize GABA by co-expressing the marker Gad2. However, most of these ACh neurons do not express vGAT, which would enable these neurons to release GABA. Taken together, we conclude that GABA co-transmission likely occurs only from a small population of ACh neurons restricted to few brain nuclei.
- Open Access
A conserved cell-type gradient across the human mediodorsal and paraventricular thalamus
The mediodorsal thalamus (MD) and adjacent midline nuclei are important for cognition and mental illness, but their cellular composition is not well defined. Using single-nucleus and spatial transcriptomics, we identified a conserved excitatory neuron gradient, with distinct spatial mapping of individual clusters. One end of the gradient was expanded in human MD compared to mice, which may be related to the expansion of granular prefrontal cortex in hominids. Moreover, neurons preferentially mapping onto the parvocellular division MD were associated with genetic risk for schizophrenia and bipolar disorder. Midbrain-derived inhibitory interneurons were enriched in human MD and implicated in genetic risk for major depressive disorder.
Open AccessA conserved cell-type gradient across the human mediodorsal and paraventricular thalamus
The mediodorsal thalamus (MD) and adjacent midline nuclei are important for cognition and mental illness, but their cellular composition is not well defined. Using single-nucleus and spatial transcriptomics, we identified a conserved excitatory neuron gradient, with distinct spatial mapping of individual clusters. One end of the gradient was expanded in human MD compared to mice, which may be related to the expansion of granular prefrontal cortex in hominids. Moreover, neurons preferentially mapping onto the parvocellular division MD were associated with genetic risk for schizophrenia and bipolar disorder. Midbrain-derived inhibitory interneurons were enriched in human MD and implicated in genetic risk for major depressive disorder.
- Open Access
- 13 January 2022
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 9 (2)
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis
Background and Objectives The central vein sign (CVS), a central linear hypointensity within lesions on T2*-weighted imaging, has been established as a sensitive and specific biomarker for the diagnosis of multiple sclerosis (MS). However, the CVS has not yet been comprehensively studied in newly developing MS lesions. We aimed to identify the CVS profiles of new white matter lesions in patients with MS followed over time and investigate demographic and clinical risk factors associated with new CVS+ or CVS− lesion development. Methods In this retrospective longitudinal cohort study, adults from the NIH MS Natural History Study were considered for inclusion. Participants with new T2 or enhancing lesions were identified through review of the radiology report and/or longitudinal subtraction imaging. Each new lesion was evaluated for the CVS. Clinical characteristics were identified through chart review. Results A total of 153 adults (95 relapsing-remitting MS, 27 secondary progressive MS, 16 primary progressive MS, 5 clinically isolated syndrome, and 10 healthy; 67% female) were included. Of this cohort, 96 had at least 1 new T2 or contrast-enhancing lesion during median 3.1 years (Q1–Q3: 0.7–6.3) of follow-up; lesions eligible for CVS evaluation were found in 62 (65%). Of 233 new CVS-eligible lesions, 159 (68%) were CVS+, with 30 (48%) individuals having only CVS+, 12 (19%) only CVS−, and 20 (32%) both CVS+ and CVS− lesions. In gadolinium-enhancing (Gd+) lesions, the CVS+ percentage increased from 102/152 (67%) at the first time point where the lesion was observed, to 92/114 (82%) after a median follow-up of 2.8 years. Younger age (OR = 0.5 per 10-year increase, 95% CI = 0.3–0.8) and higher CVS+ percentage at baseline (OR = 1.4 per 10% increase, 95% CI = 1.1–1.9) were associated with increased likelihood of new CVS+ lesion development. Discussion In a cohort of adults with MS followed over a median duration of 3 years, most newly developing T2 or enhancing lesions were CVS+ (68%), and nearly half (48%) developed new CVS+ lesions only. Importantly, the effects of edema and T2 signal changes can obscure small veins in Gd+ lesions; therefore, caution and follow-up is necessary when determining their CVS status. Trial Registration Information Clinical trial registration number NCT00001248. Classification of Evidence This study provides Class III evidence that younger age and higher CVS+ percentage at baseline are associated with new CVS+ lesion development.
- 13 January 2022
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 9 (2)
Open AccessCentral Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis
Background and Objectives The central vein sign (CVS), a central linear hypointensity within lesions on T2*-weighted imaging, has been established as a sensitive and specific biomarker for the diagnosis of multiple sclerosis (MS). However, the CVS has not yet been comprehensively studied in newly developing MS lesions. We aimed to identify the CVS profiles of new white matter lesions in patients with MS followed over time and investigate demographic and clinical risk factors associated with new CVS+ or CVS− lesion development. Methods In this retrospective longitudinal cohort study, adults from the NIH MS Natural History Study were considered for inclusion. Participants with new T2 or enhancing lesions were identified through review of the radiology report and/or longitudinal subtraction imaging. Each new lesion was evaluated for the CVS. Clinical characteristics were identified through chart review. Results A total of 153 adults (95 relapsing-remitting MS, 27 secondary progressive MS, 16 primary progressive MS, 5 clinically isolated syndrome, and 10 healthy; 67% female) were included. Of this cohort, 96 had at least 1 new T2 or contrast-enhancing lesion during median 3.1 years (Q1–Q3: 0.7–6.3) of follow-up; lesions eligible for CVS evaluation were found in 62 (65%). Of 233 new CVS-eligible lesions, 159 (68%) were CVS+, with 30 (48%) individuals having only CVS+, 12 (19%) only CVS−, and 20 (32%) both CVS+ and CVS− lesions. In gadolinium-enhancing (Gd+) lesions, the CVS+ percentage increased from 102/152 (67%) at the first time point where the lesion was observed, to 92/114 (82%) after a median follow-up of 2.8 years. Younger age (OR = 0.5 per 10-year increase, 95% CI = 0.3–0.8) and higher CVS+ percentage at baseline (OR = 1.4 per 10% increase, 95% CI = 1.1–1.9) were associated with increased likelihood of new CVS+ lesion development. Discussion In a cohort of adults with MS followed over a median duration of 3 years, most newly developing T2 or enhancing lesions were CVS+ (68%), and nearly half (48%) developed new CVS+ lesions only. Importantly, the effects of edema and T2 signal changes can obscure small veins in Gd+ lesions; therefore, caution and follow-up is necessary when determining their CVS status. Trial Registration Information Clinical trial registration number NCT00001248. Classification of Evidence This study provides Class III evidence that younger age and higher CVS+ percentage at baseline are associated with new CVS+ lesion development.
- 29 September 2020
- Published by Springer Nature
- p. 572-582
AdaBoosted Deep Ensembles: Getting Maximum Performance Out of Small Training Datasets
- 29 September 2020
- Published by Springer Nature
- p. 572-582
AdaBoosted Deep Ensembles: Getting Maximum Performance Out of Small Training Datasets
- Open Access
- 1 January 2020
- Published by Elsevier in NeuroImage: Clinical
- Vol. 28, 102499
Progressive multifocal leukoencephalopathy lesion and brain parenchymal segmentation from MRI using serial deep convolutional neural networks
- 1 January 2020
- Published by Elsevier in NeuroImage: Clinical
- Vol. 28, 102499
Open AccessProgressive multifocal leukoencephalopathy lesion and brain parenchymal segmentation from MRI using serial deep convolutional neural networks
- Open Access
Multiple Sclerosis Lesion Segmentation from Brain MRI via Fully Convolutional Neural Networks
Multiple Sclerosis (MS) is an autoimmune disease that leads to lesions in the central nervous system. Magnetic resonance (MR) images provide sufficient imaging contrast to visualize and detect lesions, particularly those in the white matter. Quantitative measures based on various features of lesions have been shown to be useful in clinical trials for evaluating therapies. Therefore robust and accurate segmentation of white matter lesions from MR images can provide important information about the disease status and progression. In this paper, we propose a fully convolutional neural network (CNN) based method to segment white matter lesions from multi-contrast MR images. The proposed CNN based method contains two convolutional pathways. The first pathway consists of multiple parallel convolutional filter banks catering to multiple MR modalities. In the second pathway, the outputs of the first one are concatenated and another set of convolutional filters are applied. The output of this last pathway produces a membership function for lesions that may be thresholded to obtain a binary segmentation. The proposed method is evaluated on a dataset of 100 MS patients, as well as the ISBI 2015 challenge data consisting of 14 patients. The comparison is performed against four publicly available MS lesion segmentation methods. Significant improvement in segmentation quality over the competing methods is demonstrated on various metrics, such as Dice and false positive ratio. While evaluating on the ISBI 2015 challenge data, our method produces a score of 90.48, where a score of 90 is considered to be comparable to a human rater.
Open AccessMultiple Sclerosis Lesion Segmentation from Brain MRI via Fully Convolutional Neural Networks
Multiple Sclerosis (MS) is an autoimmune disease that leads to lesions in the central nervous system. Magnetic resonance (MR) images provide sufficient imaging contrast to visualize and detect lesions, particularly those in the white matter. Quantitative measures based on various features of lesions have been shown to be useful in clinical trials for evaluating therapies. Therefore robust and accurate segmentation of white matter lesions from MR images can provide important information about the disease status and progression. In this paper, we propose a fully convolutional neural network (CNN) based method to segment white matter lesions from multi-contrast MR images. The proposed CNN based method contains two convolutional pathways. The first pathway consists of multiple parallel convolutional filter banks catering to multiple MR modalities. In the second pathway, the outputs of the first one are concatenated and another set of convolutional filters are applied. The output of this last pathway produces a membership function for lesions that may be thresholded to obtain a binary segmentation. The proposed method is evaluated on a dataset of 100 MS patients, as well as the ISBI 2015 challenge data consisting of 14 patients. The comparison is performed against four publicly available MS lesion segmentation methods. Significant improvement in segmentation quality over the competing methods is demonstrated on various metrics, such as Dice and false positive ratio. While evaluating on the ISBI 2015 challenge data, our method produces a score of 90.48, where a score of 90 is considered to be comparable to a human rater.
- 26 September 2017
- Published by Springer Nature
- p. 24-32
Synthesizing CT from Ultrashort Echo-Time MR Images via Convolutional Neural Networks
- 26 September 2017
- Published by Springer Nature
- p. 24-32
Synthesizing CT from Ultrashort Echo-Time MR Images via Convolutional Neural Networks
- Open Access
- 22 June 2017
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 38 (8) , 1501-1509
Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis
BACKGROUND AND PURPOSE: MR imaging can be used to measure structural changes in the brains of individuals with multiple sclerosis and is essential for diagnosis, longitudinal monitoring, and therapy evaluation. The North American Imaging in Multiple Sclerosis Cooperative steering committee developed a uniform high-resolution 3T MR imaging protocol relevant to the quantification of cerebral lesions and atrophy and implemented it at 7 sites across the United States. To assess intersite variability in scan data, we imaged a volunteer with relapsing-remitting MS with a scan-rescan at each site. MATERIALS AND METHODS: All imaging was acquired on Siemens scanners (4 Skyra, 2 Tim Trio, and 1 Verio). Expert segmentations were manually obtained for T1-hypointense and T2 (FLAIR) hyperintense lesions. Several automated lesion-detection and whole-brain, cortical, and deep gray matter volumetric pipelines were applied. Statistical analyses were conducted to assess variability across sites, as well as systematic biases in the volumetric measurements that were site-related. RESULTS: Systematic biases due to site differences in expert-traced lesion measurements were significant (P < .01 for both T1 and T2 lesion volumes), with site explaining >90% of the variation (range, 13.0–16.4 mL in T1 and 15.9–20.1 mL in T2) in lesion volumes. Site also explained >80% of the variation in most automated volumetric measurements. Output measures clustered according to scanner models, with similar results from the Skyra versus the other 2 units. CONCLUSIONS: Even in multicenter studies with consistent scanner field strength and manufacturer after protocol harmonization, systematic differences can lead to severe biases in volumetric analyses.
- 22 June 2017
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 38 (8) , 1501-1509
Open AccessVolumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis
BACKGROUND AND PURPOSE: MR imaging can be used to measure structural changes in the brains of individuals with multiple sclerosis and is essential for diagnosis, longitudinal monitoring, and therapy evaluation. The North American Imaging in Multiple Sclerosis Cooperative steering committee developed a uniform high-resolution 3T MR imaging protocol relevant to the quantification of cerebral lesions and atrophy and implemented it at 7 sites across the United States. To assess intersite variability in scan data, we imaged a volunteer with relapsing-remitting MS with a scan-rescan at each site. MATERIALS AND METHODS: All imaging was acquired on Siemens scanners (4 Skyra, 2 Tim Trio, and 1 Verio). Expert segmentations were manually obtained for T1-hypointense and T2 (FLAIR) hyperintense lesions. Several automated lesion-detection and whole-brain, cortical, and deep gray matter volumetric pipelines were applied. Statistical analyses were conducted to assess variability across sites, as well as systematic biases in the volumetric measurements that were site-related. RESULTS: Systematic biases due to site differences in expert-traced lesion measurements were significant (P < .01 for both T1 and T2 lesion volumes), with site explaining >90% of the variation (range, 13.0–16.4 mL in T1 and 15.9–20.1 mL in T2) in lesion volumes. Site also explained >80% of the variation in most automated volumetric measurements. Output measures clustered according to scanner models, with similar results from the Skyra versus the other 2 units. CONCLUSIONS: Even in multicenter studies with consistent scanner field strength and manufacturer after protocol harmonization, systematic differences can lead to severe biases in volumetric analyses.
- 1 February 2017
- Published by Elsevier in Medical Image Analysis
- Vol. 36, 2-14
Cross contrast multi-channel image registration using image synthesis for MR brain images
- 1 February 2017
- Published by Elsevier in Medical Image Analysis
- Vol. 36, 2-14
Cross contrast multi-channel image registration using image synthesis for MR brain images
- 1 February 2017
- Published by Elsevier in NeuroImage
- Vol. 146, 132-147
Robust skull stripping using multiple MR image contrasts insensitive to pathology
- 1 February 2017
- Published by Elsevier in NeuroImage
- Vol. 146, 132-147
Robust skull stripping using multiple MR image contrasts insensitive to pathology